Impact of left ventricular hypertrophy on QT prolongation and associated mortality

Heart Rhythm

Volumn 11, Issue 11, 2014, Pages 1957-1965

  Haugaa, Kristina H ^a   Martijn Bos, J ^b   Borkenhagen, Evan J ^a   Tarrell, Robert F ^a   Morlan, Bruce W ^a   Caraballo, Pedro J ^a   Ackerman, Michael J ^a,b  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

Electrocardiogram; Left ventricular hypertrophy; Mortality; QTc

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; BIOLOGICAL MARKER;

ADULT; AGE; ARTICLE; CARDIAC PATIENT; CARDIOLOGIST; CARDIOVASCULAR MORTALITY; CONTROLLED STUDY; DIABETES MELLITUS; DIALYSIS; ELECTROCARDIOGRAM; FEMALE; FOLLOW UP; GENDER; HEART LEFT VENTRICLE HYPERTROPHY; HEART RATE; HEART VALVE STENOSIS; HUMAN; HYPERTENSION; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QRS INTERVAL; QT INTERVAL; QT PROLONGATION; QTC INTERVAL; RECEIVER OPERATING CHARACTERISTIC; SURVIVOR; AGED; ALGORITHM; BLOOD; COMORBIDITY; ELECTROCARDIOGRAPHY; LONG QT SYNDROME; MIDDLE AGED; MORTALITY; PATHOPHYSIOLOGY;

AGED; ALGORITHMS; BIOLOGICAL MARKERS; COMORBIDITY; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; LONG QT SYNDROME; MALE; MIDDLE AGED;

EID: 84938678984     PISSN: 15475271     EISSN: 15563871     Source Type: Journal    
DOI: 10.1016/j.hrthm.2014.06.025     Document Type: Article

References (27)

1. Montanez A, Ruskin JN, Hebert PR, Lamas GA, Hennekens CH. Prolonged QTc interval and risks of total and cardiovascular mortality and sudden death in the general population: a review and qualitative overview of the prospective cohort studies. Arch Intern Med 2004;164:943-948.
2. Straus SM, Kors JA, De Bruin ML, Van der Hooft CS, Hofman A, Heeringa J, Deckers JW, Kingma JH, Sturkenboom MCJM, Stricker BHC, Witteman JCM. Prolonged QTc interval and risk of sudden cardiac death in a population of older adults. J Am Coll Cardiol 2006;47:362-367.
3. Dekker JM, Crow RS, Hannan PJ, Schouten EG, Folsom AR. Heart rate-corrected QT interval prolongation predicts risk of coronary heart disease in black and white middle-aged men and women: the ARIC study. J Am Coll Cardiol 2004;43:565-571.
4. Soliman EZ, Howard G, Cushman M, Kissela B, Kleindorfer D, Le A, Judd S, McClure LA, Howard VJ. Prolongation of QTc and risk of stroke: the REGARDS (REasons for Geographic and Racial Differences in Stroke) study. J Am Coll Cardiol 2012;59:1460-1467.
5. Haugaa KH, Bos JM, Tarrell RF, Morlan BW, Caraballo PJ, Ackerman MJ. Institution-wide QT alert system identifies patients with a high risk of mortality. Mayo Clin Proc 2013;88:315-325.
6. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med 2004;350:1013-1022.
7. Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM. Azithromycin and the risk of cardiovascular death. N Engl J Med 2012;366:1881-1890.
8. Drew BJ, Ackerman MJ, Funk M, Gibler WB, Kligfeld P, Menon V, Phillipides GJ, Roden DM, Zareba W. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. Circulation 2010;121:1047-1060.
9. De Bruin ML, Langendijk PN, Koopmans RP, Wilde AA, Leufkens HGm, Hoes AW. In-hospital cardiac arrest is associated with use of non-antiarrhythmic QTc-prolonging drugs. Br J Clin Pharmacol 2007;63:216-223.
10. Sullivan JM, Vander Zwaag RV, el-Zeky F, Ramanathan KB, Mirvis DM. Left ventricular hypertrophy: effect on survival. J Am Coll Cardiol 1993;22: 508-513.
11. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990;322:1561-1566.
12. Levy D, Anderson KM, Savage DD, Balkus SA, Kannel WB, Castelli WP. Echocardiographically detected left ventricular hypertrophy: prevalence and risk factors: the Framingham Heart Study. Ann Intern Med 1988;108:7-13.
13. Oikarinen L, Nieminen MS, Viitasalo M, Toivonen L, Wachtell K, Papademetriou V, Jern S, Dahlof B, Devereux RB, Okin PM. Relation of QT interval and QT dispersion to echocardiographic left ventricular hypertrophy and geometric pattern in hypertensive patients: the LIFE study. The Losartan Intervention For Endpoint Reduction. J Hypertens 2001;19:1883-1891.
14. Oikarinen L, Nieminen MS, Viitasalo M, Toivonen L, Jern S, Dahlof B, Devereux RB, Okin PM. QRS duration and QT interval predict mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention for Endpoint Reduction in Hypertension Study. Hypertension 2004;43: 1029-1034.
15. Johnson JN, Grifoni C, Bos JM, Saber-Ayad M, Ommen SR, Nistri S, Cecchi F, Olivotto I, Ackerman MJ. Prevalence and clinical correlates of QT prolongation in patients with hypertrophic cardiomyopathy. Eur Heart J 2011;32:1114-1120.
16. Hammill SC, Andrist EM, Thorkelson LA. Electrocardiogram interpreting technician: training and role in a contemporary electrocardiogram practice. J Electrocardiol 2008;41:442-443.
17. Bazett HC. An analysis of the time-relations of electrocardiography. Heart 1920;7:353-370.
18. Sagie A, Larson MG, Goldberg RJ, Bengtson JR, Levy D. An improved method for adjusting the QT interval for heart rate (the Framingham Heart Study). Am J Cardiol 1992;70:797-801.
19. Rautaharju PM, Surawicz B, Gettes LS, et al. AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram, Part IV: the ST segment, T and U waves, and the QT interval: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society. Endorsed by the International Society for Computerized Electrocardiology. J Am Coll Cardiol 2009;53:982-991.
20. Sokolow M, Lyon TP. The ventricular complex in left ventricular hypertrophy as obtained by unipolar precordial and limb leads. Am Heart J 1949;37:161-186.
21. Casale PN, Devereux RB, Alonso DR, Campo E, Kligfield P. Improved sexspecific criteria of left ventricular hypertrophy for clinical and computer interpretation of electrocardiograms: validation with autopsy findings. Circulation 1987;75:565-572.
22. CredibleMedss . www.qtdrugs.org.Accessed July 2012.
23. Levy D, Labib SB, Anderson KM, Christiansen JC, Kannel WB, Castelli WP. Determinants of sensitivity and specificity of electrocardiographic criteria for left ventricular hypertrophy. Circulation 1990;81:815-820.
24. Panikkath R, Reinier K, Uy-Evanado A, Teodorescu C, Gunson K, Jui J, Chugh SS. Electrocardiographic predictors of sudden cardiac death in patients with left ventricular hypertrophy. Ann Noninvasive Electrocardiol 2013;18: 225-229.
25. Taggart NW, Haglund CM, Tester DJ, Ackerman MJ. Diagnostic miscues in congenital long-QT syndrome. Circulation 2007;115:2613-2620.
26. Sorajja P, Ommen SR, Holmes DR Jr, Dearani JA, Rihal CS, Gersh BJ, Lennon RJ, Nishimura RA. Survival after alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation 2012;126:2374-2380.
27. Kowey PR, Friechling TD, Sewter J, Wu Y, Sokil A, Paul J, Nocella J. Electrophysiological effects of left ventricular hypertrophy: effect of calcium and potassium channel blockade. Circulation 1991;83:2067-2075.